CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
2019
Purpose of Review
To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+ MBC) as well as current controversies and evolving areas of research.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
50
References
60
Citations
NaN
KQI